RxDoctor Payments Data

Tammy Sutton Carnes

Nurse Practitioner · Corbin, KYNPI 1700173572

Payments from drug & device makers

$6,204in general payments, 2019–2025

Across 179 payments — averaging $34.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Neurocrine Biosciences, Inc.$725
  • Vanda Pharmaceuticals Inc.$724
  • AbbVie$661
  • Axsome Therapeutics, Inc.$514
  • Alkermes, Inc.$488
  • plus $2K from 12 others

What the payments were for

  • Food & beverage$6,204100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,204 in reported general payments places this provider in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$18,468
Medicare patients
56
Services billed
173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl40$56,222
Invega SustennaPaliperidone Palmitate17$53,437
CaplytaLumateperone Tosylate17$27,445
Clomipramine Hcl13$6,743
Aripiprazole102$5,464
Divalproex Sodium ErDivalproex Sodium26$3,404
Oxcarbazepine49$2,503
Quetiapine Fumarate156$2,426
Divalproex Sodium38$2,395
Asenapine Maleate22$2,295
Guanfacine Hcl ErGuanfacine Hcl16$2,090
Desvenlafaxine Succinate ErDesvenlafaxine Succinate35$1,699
Duloxetine Hcl66$1,396
Buspirone Hcl168$1,330
Mirtazapine107$1,297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$661$56,22240 claims
Johnson & JohnsonInvega Sustenna$287$53,43717 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,130$27,44517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Corbin

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →